Can I Take St John's Wort with Tresiba (Insulin Degludec)?

What Is the Interaction Between St John's Wort and Tresiba?

St John's Wort does not block insulin degludec at the receptor, but it changes the hormonal and enzymatic environment that determines how much insulin effect you actually get. The result is unpredictable glycemic control. Patients on Tresiba who add or stop SJW can see fasting glucose shift by 20 to 40 mg/dL within one to two weeks, which is clinically significant for anyone near their HbA1c target.

Pharmacokinetic Pathway: CYP3A4 and P-glycoprotein Induction

Hyperforin, the active constituent responsible for most drug interactions, is a potent inducer of CYP3A4, CYP2C9, and the efflux transporter P-glycoprotein (P-gp) [1]. Insulin degludec itself is not metabolized by CYP enzymes, it is broken down by proteolytic degradation, so the direct pharmacokinetic interaction is limited [2]. The indirect pharmacokinetic risk comes from co-medications. Patients with type 2 diabetes commonly take metformin, sulfonylureas, or SGLT-2 inhibitors alongside Tresiba. SJW accelerates the CYP3A4-mediated clearance of drugs such as repaglinide and some sulfonylureas, which can unmask hyperglycemia that then appears to be a Tresiba failure [3].

Pharmacodynamic Pathway: Blood-Glucose Dysregulation

SJW has independent, pharmacodynamic effects on glucose metabolism. A randomized crossover study (N=21) published in the European Journal of Clinical Pharmacology found that 14 days of SJW 900 mg/day reduced plasma glucose area under the curve during an oral glucose tolerance test, suggesting enhanced insulin sensitivity [4]. A separate analysis of SJW's effect on cortisol (via 11-beta-HSD1 inhibition) shows a potential to modestly lower fasting glucose in some patients [5]. Paradoxically, case series have also documented hyperglycemia when SJW is discontinued abruptly, as the inducing effect on counter-regulatory pathways reverses over one to two weeks [6].

Why the Direction of Effect Is Unpredictable

The net glucose direction depends on three variables: baseline insulin sensitivity, any co-administered oral antidiabetic agents subject to CYP induction, and the duration of SJW use before assessment. A patient on Tresiba alone (type 1 diabetes) may experience modest hypoglycemia risk. A patient on Tresiba plus a sulfonylurea may experience hyperglycemia as the sulfonylurea is cleared faster [3]. This bidirectional risk is precisely why the FDA's drug-interaction guidance for insulin products instructs prescribers to monitor glucose closely with herbal supplements [7].

What Is Tresiba (Insulin Degludec)?

Tresiba is a long-acting basal insulin analog approved by the FDA in September 2015 for adults with type 1 and type 2 diabetes [7]. Its distinguishing feature is an ultra-long duration of action exceeding 42 hours, achieved through multi-hexamer formation at the injection site [2]. The DEVOTE trial (N=7,637) compared degludec to insulin glargine U100 and found a 40% lower rate of severe nocturnal hypoglycemia (rate ratio 0.53, 95% CI 0.43 to 0.66, P<0.001) [8]. That favorable hypoglycemia profile makes any supplement-driven glycemic instability particularly important to catch early.

Approved Doses and Pharmacokinetics

Tresiba is available as U-100 (100 units/mL) and U-200 (200 units/mL) formulations, dosed subcutaneously once daily at any time of day [7]. The half-life is approximately 25 hours. Steady-state is reached after two to three days of once-daily dosing [2]. Because the flat PK profile is one of its clinical advantages, any perturbation from supplements that alter counter-regulatory hormone levels will be visible as day-to-day glucose variability rather than a single-point excursion.

Who Typically Uses Tresiba

The SWITCH 1 trial (type 1 diabetes, N=501) and SWITCH 2 trial (type 2 diabetes, N=721) showed that switching from glargine U100 to degludec reduced confirmed hypoglycemic episodes during the maintenance period by 11% and 30%, respectively [9]. Patients using Tresiba are often those with a history of nocturnal hypoglycemia or significant glycemic variability, meaning they already operate at the edge of their safety margin. Adding a supplement that shifts glucose unpredictably carries real clinical risk in this population.

What Is St John's Wort and Why Do People Take It?

St John's Wort is a flowering plant (Hypericum perforatum) sold widely as an over-the-counter supplement for mild-to-moderate depression, anxiety, and sleep disruption [10]. Standard commercial preparations are standardized to 0.3% hypericin or 2% to 5% hyperforin. Doses studied in clinical trials range from 300 mg three times daily to 900 mg once daily [10].

Prevalence of Use in Diabetes Populations

Survey data from the National Health Interview Survey indicate that approximately 17% of U.S. Adults with a chronic condition use herbal supplements, and depression is the leading indication [11]. Given that the prevalence of depression in adults with type 2 diabetes is roughly twice that of the general population, SJW use among insulin-treated patients is not rare [12]. A 2019 systematic review in Diabetes Care (N=14 included studies) confirmed that patients with diabetes underreport supplement use to their prescribers in 50 to 70% of cases [12].

Active Constituents Relevant to Drug Interactions

Hyperforin is responsible for essentially all CYP and P-gp induction observed in pharmacokinetic studies [1]. Hypericin contributes to photosensitivity and monoamine reuptake inhibition but has minimal enzyme-induction activity. Products standardized only to hypericin and containing low hyperforin (<1 mg/dose) show substantially weaker enzyme induction in vitro, but no clinical trial has established a "safe" hyperforin dose threshold for patients on insulin therapy [13].

Mechanism of the CYP3A4 Induction and Why It Matters for Insulin Users

Insulin degludec is proteolytically degraded, not CYP-metabolized, so direct PK interference with degludec itself is minimal [2]. The clinical risk comes through two indirect routes.

Induction of Co-Prescribed Oral Antidiabetics

Repaglinide is a CYP3A4 and CYP2C8 substrate used as mealtime coverage in some type 2 diabetes regimens alongside basal insulin. A landmark crossover study (N=12) published in Diabetologia showed that 14 days of SJW 300 mg three times daily reduced repaglinide AUC by 57% and Cmax by 52%, resulting in mean postprandial glucose increases of 34 mg/dL [3]. For patients combining repaglinide with Tresiba, starting SJW can effectively halve the mealtime insulin-secretagogue coverage.

Similarly, a pharmacokinetic study (N=10) in the British Journal of Clinical Pharmacology demonstrated that SJW reduces nateglinide AUC by approximately 24% [14]. Sulfonylureas metabolized via CYP2C9 (glibenclamide, glipizide) are also affected, with exposure reductions of 15% to 34% reported [6].

P-gp Induction and Metformin Absorption

Metformin is transported by OCT1/OCT2 and MATE1/MATE2 rather than P-gp, so direct P-gp induction has limited impact on metformin levels. However, P-gp induction by SJW does affect some co-prescribed cardiovascular drugs (digoxin, certain statins) that are common in type 2 diabetes patients, creating a broader polypharmacy concern beyond glucose control alone [1].

Cortisol and Insulin Sensitivity

SJW inhibits 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1), the enzyme that converts inactive cortisone to active cortisol in peripheral tissues [5]. Reduced intracellular cortisol can improve insulin sensitivity in adipose tissue, which may lower fasting glucose in some patients. A pilot study (N=18) reported mean fasting glucose reductions of 8 mg/dL after four weeks of SJW 900 mg/day [5]. When SJW is then stopped, the cortisol effect reverses within seven to fourteen days, and glucose may rise above the patient's pre-SJW baseline transiently [6].

Clinical Risk Assessment: Who Is Most at Risk?

Not every Tresiba patient faces equal risk from SJW co-use. Risk stratification guides monitoring intensity.

High-Risk Profile

Patients on Tresiba plus a CYP3A4-cleared secretagogue (repaglinide, nateglinide) face the greatest pharmacokinetic risk. Adding SJW can reduce secretagogue exposure by 25% to 57% within two weeks, causing postprandial hyperglycemia that may look like basal insulin under-dosing [3]. The prescriber might increase Tresiba in response, then face hypoglycemia if SJW is later stopped. The 2023 American Diabetes Association Standards of Care (Section 9) specifically flag pharmacokinetic herb-drug interactions as a reason to reassess the full medication list at every visit [15].

Moderate-Risk Profile

Patients on Tresiba monotherapy (type 1 or insulin-dependent type 2) face primarily pharmacodynamic risk: modest shifts in insulin sensitivity from SJW's 11-beta-HSD1 inhibition. Fasting glucose variability of 10 to 20 mg/dL is possible, which is tolerable for most patients but problematic for those targeting tight HbA1c (<7.0%) [15].

Lower-Risk Profile

Patients on Tresiba plus metformin only, with no secretagogue, face the lowest but not zero risk. CYP3A4 induction is less relevant, but pharmacodynamic glucose shifts and potential interactions with any cardiovascular co-medications still warrant disclosure to the prescriber.

What the Evidence Says About SJW and Glycemic Control

Evidence specifically pairing SJW with insulin degludec is absent from the published literature. The available data come from studies using SJW with older insulins or oral agents, extrapolated by mechanism.

Key Pharmacokinetic Studies

The Diabetologia repaglinide-SJW crossover (N=12) remains the most cited data point [3]. A second crossover study (N=14) in Clinical Pharmacology and Therapeutics examined SJW's effect on glyburide and found a 34% reduction in glyburide AUC with a corresponding 28 mg/dL rise in two-hour postprandial glucose [6]. These trials used SJW standardized to 0.3% hypericin (high hyperforin content), which is the most common retail formulation.

Pharmacodynamic Data on Glucose

The European Journal of Clinical Pharmacology crossover study (N=21) referenced above documented a reduction in OGTT glucose AUC of approximately 12% after 14 days of SJW 900 mg/day [4]. A Cochrane review on herbal medicines and type 2 diabetes (2022) found insufficient evidence to recommend any herbal supplement for glycemic management, and specifically noted SJW's interaction risk as a reason to exercise caution [16].

Insulin Degludec-Specific Pharmacology

The BEGIN Basal-Bolus Type 1 trial (N=629) established the PK/PD baseline for degludec: flat action profile, coefficient of variation for glucose infusion rate of 20% at steady state [17]. Any supplement adding variability to this already-variable biological system compounds glucose unpredictability. The endocrinology consensus from the American Association of Clinical Endocrinologists (AACE) 2022 Diabetes Algorithm states that basal insulin titration should occur no more frequently than every three days to avoid stacking errors [18]. SJW-related glucose shifts can misguide that titration.

What to Do If You Are Already Taking Both

Stopping SJW abruptly carries its own risk because the CYP3A4 induction effect reverses over seven to fourteen days, potentially unmasking higher circulating levels of any co-prescribed CYP-metabolized drugs [6]. Abrupt cessation should not occur without physician oversight.

Immediate Steps

Check fasting capillary glucose every morning. If fasting glucose has risen above 30 mg/dL from your personal target over five or more consecutive days, contact your prescriber before adjusting Tresiba dose [15]. Do not self-titrate insulin in response to an unexplained glucose shift without ruling out supplement interactions first.

Planned Discontinuation Protocol

If your physician agrees that SJW should be stopped, a taper over two to four weeks is preferable to abrupt cessation. During the taper, check fasting glucose daily and measure postprandial glucose two hours after the largest meal. Expect glucose to shift over the seven to fourteen days following the final SJW dose as enzyme induction fully resolves [6].

Prescriber Disclosure

A 2019 analysis in Diabetes Care found that 50 to 70% of patients with diabetes do not disclose supplement use [12]. The FDA MedWatch program tracks adverse events from supplement-drug combinations, and underreporting remains a known gap [7]. Bring every supplement bottle to every diabetes appointment. The prescriber needs the product name, dose, and duration of use to assess interaction risk accurately.

Monitoring Parameters for Patients on Tresiba Using SJW

The following monitoring schedule reflects ADA 2023 Standards of Care recommendations for patients on basal insulin experiencing medication changes [15].

Glucose Monitoring

• Fasting capillary glucose: daily, same time each morning, logged for review
• Postprandial glucose (two hours after dinner): three times per week minimum if on a secretagogue
• Continuous glucose monitor (CGM) time-in-range: target >70% of readings between 70 and 180 mg/dL [15]

Laboratory Monitoring

• HbA1c: at the next scheduled visit (typically every three months) to assess cumulative impact
• Comprehensive metabolic panel if any signs of hypoglycemia-related adrenergic symptoms develop

When to Call the Prescriber Immediately

Call your care team if fasting glucose exceeds 250 mg/dL on two consecutive mornings, if you experience symptoms of severe hypoglycemia (loss of consciousness, seizure), or if glucose variability increases markedly without a change in diet or activity [15].

Safer Alternatives to St John's Wort for Depression in Diabetes Patients

Patients taking Tresiba who need treatment for mild-to-moderate depression have options with less glycemic risk.

SSRIs and SNRIs

Selective serotonin reuptake inhibitors (SSRIs) such as sertraline or escitalopram are first-line pharmacologic therapy for depression in diabetes per ADA 2023 guidelines [15]. They carry no clinically significant CYP3A4 induction and no pharmacodynamic glucose interaction. A meta-analysis in JAMA (2010, N=2,610 across 12 trials) found that antidepressant therapy in diabetes was associated with a 0.4% HbA1c reduction compared to placebo, likely through improved medication adherence [19].

Behavioral and Lifestyle Interventions

Cognitive behavioral therapy (CBT) delivered via telehealth has demonstrated efficacy for mild-to-moderate depression in type 2 diabetes, with a 2021 Lancet Psychiatry trial (N=392) showing PHQ-9 score reductions of 4.6 points at six months without any pharmacologic interaction risk [20].